TON - November 2024 Vol 17, No 4

Oncology nurses are often the first to hear about patients’ therapy-induced side effects. Understanding these challenges can help maximize your patients’ quality of life and keep their treatment plan on schedule. Read More ›

“Neither my education in nursing school nor graduate school prepared me for neuro-oncology,” writes Marissa Panzer, DNP, AGPCNP, AOCNP, who shares her experiences navigating the oncology world as a nurse practitioner. Read More ›

As the days grow shorter and darker, it’s easy to fall prey to feelings of sadness and isolation, and although you cannot always avoid experiencing seasonal affective disorder, you can make lifestyle changes to manage it and prevent future episodes. Read More ›

Biomarker testing is crucial in guiding treatment choices by pinpointing individuals who stand to gain from specific regimens, ultimately enhancing patient results. Nevertheless, the application of guideline-endorsed biomarker testing for advanced non–small cell lung cancer patients varies. Read More ›

MCLA-129 is a Biclonics-based product that can be categorized as a common light chain/bispecific antibody used to target EGFR and c-MET while enhancing antibody-dependent cellular cytotoxicity. Read More ›

Prostate cancer ranks as the second most common cause of cancer-related deaths among men in the United States. Aggressive forms of this cancer are linked to mutations in homologous recombination repair genes. Read More ›

Despite recommendations, genetic testing for advanced prostate cancer is not widely used and may not be readily accepted by patients. This analysis investigated the attitudes and decisional conflicts surrounding genetic testing and the differences between White and non-White patients. Read More ›

Disparities have been extensively documented in prostate cancer screening uptake and shared decision-making conversations among racial and sexual minorities. Yet, the impact of racial/ethnic identity and sexual orientation on prostate-specific antigen testing uptake remains uncertain. Read More ›

Messenger ribonucleic acid (mRNA)-4157 is an innovative approach to personalized neoantigen therapy. It utilizes mRNA to enhance the body’s natural immune response against tumor cells by targeting specific mutations unique to each patient. Read More ›

A pediatric hematology/oncology nurse shares her personal experiences witnessing the significant increase in survival of young patients with cancer over the past few decades, preserving her well-being, and making personal connections with her patients and community. Read More ›